SEARCH

SEARCH BY CITATION

References

  • 1
    Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108: S147334.
  • 2
    Demoly P, Allaert FA, Lecasble M, Bousquet J, PRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58: 672675.
  • 3
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24: 758764.
  • 4
    Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22: 345361.
  • 5
    Dessi P, Allaert FA, Urbinelli R, Verriere JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allerg Immunol (Paris) 1998;30: 277283.
  • 6
    Levebvre S, Daures J-P, Sartor F, Walckiers D, El Hasnaoui A. Estimination of French epilepsy prevalence rate from drug sales data. Pharmacoepidemiology and drug safety 2001;10: S57S58.
  • 7
    De Zelicourt M, Buteau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000;9: 8895.
  • 8
    Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T. Cost of colorectal cancer in France in 1999. Gastroenterol Clin Biol 2003;27: 2227.
  • 9
    Marshall JB. Socio-economic costs of allergic diseases. In: European Allergy White Paper, UCB Institute of Allergy, 1997; 98110.
  • 10
    McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994;73: 3539.
  • 11
    Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99: 2227.
  • 12
    Storms W, Meltzer EO, Nathan RA. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997;99: S820824.
  • 13
    Sculpher M. The role and estimation of productivity costs in economic evaluation. In: DrummondM, McGuireA, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 94112.
  • 14
    Wang PS, Beck A, Berglund P, Leutzinger JA, Pronk N, Richling D et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med 2003;45: 13031311.
  • 15
    Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments. Validation studies in allergic rhinitis. Clinical Drug Investigation 1996;11: 278288.
  • 16
    Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999;41: 948953.
  • 17
    Weiss KB. Cost implications of upper respiratory allergic diseases. J Allergy Clin Immunol 1998;101: S383385.
  • 18
    Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99: S773780.
  • 19
    Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103: 401407.
  • 20
    Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003;21: 116122.
  • 21
    Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999;103: 5459.
  • 22
    Didier A, Chanal I, Klossek JM, Mathieu J. La rhinite allergique: le point de vue du patient. Rev Fr Allergol 1999;39: 171185.
  • 23
    Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114: 838844.
  • 24
    Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Method for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.
  • 25
    Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13: 17.
  • 26
    Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14: 171189.
  • 27
    Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19: 32193236.
  • 28
    Heyse J, Cook J, Carides G. Statistical considerations in analysing health care resource utilization and cost data. In: DrummondM, McGuireA, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001: 215235.
  • 29
    Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111: 296300.